Pseudocholinesterase deficiency and electroconvulsive therapy

J ECT. 2007 Sep;23(3):198-200. doi: 10.1097/YCT.0b013e318070c686.

Abstract

Clinically significant pseudocholinesterase deficiency is a relatively uncommon disorder, but when present, it presents clinicians with challenges regarding medication administration. This is especially true in cases of patients receiving electroconvulsive therapy (ECT), as the presence of pseudocholinesterase deficiency limits the use of certain muscle relaxants. The authors describe a patient receiving ECT for treatment of his depression, who also possessed an unsuspected pseudocholinesterase deficiency. This was diagnosed after the patient was given succinylcholine, did not spontaneously recover motor function, and eventually required intubation. Subsequent ECT treatments were then managed with an alternative muscle relaxant which was not dependent on pseudocholinesterase for termination of action.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Butyrylcholinesterase / deficiency*
  • Depressive Disorder / complications
  • Depressive Disorder / therapy*
  • Electroconvulsive Therapy*
  • Humans
  • Male
  • Metabolism, Inborn Errors / complications
  • Metabolism, Inborn Errors / diagnosis
  • Metabolism, Inborn Errors / enzymology*
  • Neuromuscular Depolarizing Agents / adverse effects
  • Recovery of Function / drug effects
  • Succinylcholine / adverse effects

Substances

  • Neuromuscular Depolarizing Agents
  • Butyrylcholinesterase
  • Succinylcholine